Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Overview of attention for article published in Journal of Clinical Oncology, November 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 6 news outlets
policy: 1 policy source
twitter: 28 X users

googleplus: 1 Google+ user
guideline: 2 clinical guideline sources

Readers on

mendeley: 377 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Pembrolizumab (Keytruda) classical Hodgkin Lymphoma – Details - Pembrolizumab (Keytruda) cHL - Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 07 Jul 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.